Neutrophil adhesion to interleukin-1 (IL-1)-stimulated human umbilical vein endothelial cells (HUVEC) involves the CD18 family of leukocyte integrins (lymphocyte function-associated antigen-1 [LFA-11, Mac-1, and ~150.95) and LECAM-1 (DREG-56/LEU-8/LAM-l antigen) on neutrophils and intercellular adhesion molecule-l (ICAM-l) and endothelial leukocyte adhesion molecule-1 (ELAM-1) on the endothelium. In this study, we compare CD18-independent adhesion pathways mediated by neutrophil LECAM-1 and endothelial ELAM-1 and find that these two pathways overlap in a variety of assays: (1) anti-LECAM-1 and anti-ELAM-I monoclonal antibody (MoAb) inhibit neutrophil binding to HUVEC, and the inhibitory effect is not additive; (2) anti-LECAM-1 MoAb, like anti-ELAM-1 MoAb, inhibits neutrophil binding to HUVEC stimulated for 3 hours with IL-1, but not to HUVEC EUTROPHIL extravasation during the acute inflam-
Neutrophil adhesion to interleukin-1 (IL-1)-stimulated human umbilical vein endothelial cells (HUVEC) involves the CD18 family of leukocyte integrins (lymphocyte function-associated antigen-1 [LFA-11, Mac-1, and ~150.95) and LECAM-1 (DREG-56/LEU-8/LAM-l antigen) on neutrophils and intercellular adhesion molecule-l (ICAM-l) and endothelial leukocyte adhesion molecule-1 (ELAM-1) on the endothelium. In this study, we compare CD18-independent adhesion pathways mediated by neutrophil LECAM-1 and endothelial ELAM-1 and find that these two pathways overlap in a variety of assays: (1) anti-LECAM-1 and anti-ELAM-I monoclonal antibody (MoAb) inhibit neutrophil binding to HUVEC, and the inhibitory effect is not additive; (2) anti-LECAM-1 MoAb, like anti-ELAM-1 MoAb, inhibits neutrophil binding to HUVEC stimulated for 3 hours with IL-1, but not to HUVEC EUTROPHIL extravasation during the acute inflam-N matory response is a multistep process requiring induced expression of adhesion molecules on vascular endothelium, transient adhesion of circulating neutrophils to the activated endothelium, and, finally, transmigration of the neutrophils into the inflamed tissue. Numerous studies have shown that the leukocyte integrins lymphocyte functionassociated antigen-1 (LFA-1) (CDlla/CD18), Mac-1 (CDllb/CD18), and p150,95 (CDlldCD18) (collectively termed the CD18 family) are crucial for neutrophil adhesion and transmigration.ll Furthermore, patients with leukocyte adhesion deficiency (LAD), an inherited deficiency in the expression of all three CD18 molecules, have a defective neutrophil response to inflammation? Skin lesions in these patients are characteristically devoid of neutrophils, despite high levels of neutrophils in the circulation? LFA-14x5 and, more recently, Mac-15 have been shown to interact with intercellular adhesion molecule-1 (ICAM-1) on stimulated endothelium, although other ligands may also be used.
A second family of related molecules has been defined, termed selectins or LECCAMS,~ that is known to be of importance in leukocyte-endothelia1 cell interactions. The selectin/LECCAM family is composed of endothelial leukocyte adhesion molecule-1 (ELAM-l), an inducible endothelial antigen'.'; GMP-140, an inducible endothelial and platelet antigen'.'"; and the lymphocyte peripheral lymph node homing recept~r,~'-'~ referred to here as LECAM-1. LECAM-1 was first defined as a homing receptor in the mouse by the MEL-14 monoclonal antibody (MoAb)" and has subsequently been identified in defined independently as the LAM-1 antigen," and shown to be identical to the Leu-8 and TQ-1 differentiation antigens.16.M LECAM-1 is also expressed on neutrophils and has been implicated in neutrophil extravasation in the mouse. 21.22 In vivo administration of MEL-14, an anti-LECAM-1 MoAb, inhibits neutrophil extravasation into the inflamed peritoneum and to subcutaneous sites of More recently, we have developed the DREG series of MoAbs stimulated for 8 hours, by which time ELAM-1 expression is downregulated; (3) anti-ELAM-1 MoAb has no effect on transendothelial migration, a CD18-dependent, LECAM-1-independent neutrophil function. Interestingly, anti-ELAM MoAb has a reduced but significant inhibitory effect on the adhesion of activated neutrophils that have shed their cellsurface LECAM-1. We also show that neutrophil binding to ELAM-1-transfected L cells is inhibited not only by anti-ELAM-1 but also by anti-LECAM-I MoAb. These results suggest that LECAM-1 and ELAM-1 can operate in the same adhesion pathway, possibly as a receptor-counterreceptor pair. LECAM-1 and ELAM-I are likely to interact with other ligands as well, perhaps through carbohydrate determinants that modify more than one glycoprotein. In this report, we compare adhesion pathways mediated by LECAM-1 on neutrophils and ELAM-1 on HUVEC. We find that LECAM-l-dependent and ELAM-l-dependent adhesion are similar in a variety of assays, and are both independent of CDWICAM-1 adhesion events. Our results show that MoAbs to ELAM-1 and LECAM-1 inhibit a common pathway of leukocyte-endothelial cell adhesion, and that anti-LECAM-1 MoAbs inhibit neutrophil binding to ELAM-1-transfected fibroblasts. Thus, these two LECCAMs/selectins may represent a receptor-counterreceptor pair involved in neutrophil interaction with inflamed endo-806 KISHIMOTO ET AL thelium. Other ligands for both LECAh4-1 and ELAM-1 are likely to exist as well.
MATERIALS AND METHODS
Isolation of peripheral blood neutrophils. Venous blood samples from healthy adults or from patients with a severe form of LAD (patients 1 and 9 in ref. 3) were collected in the presence of citrate or heparin, dextran-sedimented, and centrifuged over Ficollhypaque gradients.
MoAbs. MoAbs against LECAM-1 (DREG-56)," CD18 (R15.7)F ICAM-lICD54 (R6.5),5 HLA-A2 (BB7),27 LFA-3 (TS2/ 9)," HCAMiCD44 (H2-7),29 and T200iCD45 (L3B12)30 have been described.
Antibodies against ELAM-1 were generated by immunization of mice with H W E C that had been stimulated with interleukin-1 (IL-1) for 3 hours at 37°C. Hybridoma supernatants were screened for the ability to stain stimulated but not unstimulated HUVEC. Two hybridomas, CL2 and CL3, were subcloned. Both MoAbs partially inhibited neutrophil binding to stimulated HUVEC (see Results) and specifically stained COS and L cells transfected with ELAM-1 cDNA, but not with irrelevant cDNAs.
The MoAbs used in this study were purified, titered, and used at a concentration that produced maximal inhibitory effect (R6.5, R15.7, CL2, and CL3 MoAb were used at 10 kg/mL, DREG-56 was used at 20 KgimL). Control MoAbs were used at the same concentrations. F(ab')* fragment?' of CL2, CL3, and R6.5 were used for antibody inhibition assays.
HUVEC were harvested and maintained as previously described?,'* Briefly, cells from 5 to 10 umbilical cords were pooled and plated in RPMI 1640 containing 10% fetal calf serum, antibiotics, heparin (0.1 mg/mL), and endothelial growth factor (0.05 mgimL). Isolation of HUVEC was confirmed by acLDL binding and factor VI11 expression, as previously d e~c r i b e d . '~~~ Visually confluent monolayers were prepared from first passage cells on 25-mm round glass coverslips precoated with 0.1% gelatin. For neutrophil adherence assays, HUVEC were stimulated with IL-1 (3 U/mL; Genzyme, Cambridge, MA) for 3 to 4 hours or 8 hours for some experiments.
A visual adherence assay has been described in detail elsewhere.s~'2 Briefly, stimulated HUVEC monolayers on 25-mm round glass coverslips were washed three times in phosphate-buffered saline (PBS) and immediately inserted into a modified Sykes-Moore chamber. Untreated neutrophils or neutrophils treated with MoAb (10 minutes, 25°C) or with the chemoatractant fMLP (10 minutes, 37°C) were injected into the chamber and allowed to settle on to the monolayer for 500 seconds. The number of neutrophils in contact with the monolayer was determined by counting 10 high-power fields (50 x objective).
The chamber was then inverted for an additional 500 seconds so that only adherent cells remained attached to the monolayer. Results are presented as percent adherence. In some experiments, the percentage of neutrophils that transmigrate through the HUVEC monolayer was determined as previously de~cribed.5.'~ Mouse L cells were transfected by diethyl aminoethyl (DEAE)-Dextran, as previously de~cribed.'~ Briefly, L cells were plated at 2 x lo6 cells per 10-cm plate the day before transfection, so that the plates were 60% to 70% confluent the next day. The cells were transfected with cesium-purified DNA (20 Kgiplate) in RPMI 1640 containing 10% NuSerum IV (Collaborative Research, Bedford, MA), 400 llgimL DEAE-Dextran, and 50 kmol/L chloroquine for 4 hours and then shocked for 2 minutes with 10% dimethyl sulfoxide (DMSO). The day after transfection the L cells were harvested with trypsin/EDTA, pooled, and then replated in 3.5-cm plates to give 40% to 60% confluent plates the
Preparation of H W C .

Neutrophil adherence to H W E C .
Transfection of L cells. Neutrophils (2 x lo"/ mL in HEPES-buffered DME) were pretreated with MoAb for 15 minutes at 25°C or activated with recombinant C5a (5 x mol/L; Sigma, St Louis, MO) for 15 minutes at 37°C. One milliliter of cells was added to each 3.5-cm plate containing 40% to 60% confluent L cells, 48 hours after transfection. The plates were subjected to gentle rotation (60 rpm) on a gyrotory shaker for 15 minutes at 25°C. The plates were washed by four rounds of aspirating the plate followed by gently filling the plate with 2 mL of DME. The remaining adherent cells were fixed with DME containing 2% glutaraldehyde and then quantitated visually by counting 10 high-power microscopic fields ( 2 0~ objective). To negate variation in L cell density, the number of L cells per field was also counted. The results were calculated as (adherent neutrophils/field)/(L cellsifield). Antibody inhibition is presented as percent of media control.
Neutrophil adherence to transfected L cells.
RESULTS
ELAM-1 and ICAM-1 mediate distinct adhesion pathways.
Freshly isolated human peripheral blood neutrophils bound to 11-1-stimulated HUVEC monolayers (3 to 4 hours, 3 U/mL) with greater than 90% efficiency (Fig 1) . As previ- 
MOA^.^' Luscinskas et
previously demonstrated that ELAM-1-dependent adhesion does not require neutrophil CD18. We confirm and extend these findings by showing that anti-ELAM-1 and anti-ICAM-1 MoAbs have an additive inhibitory effect on neutrophil binding to stimulated HUVEC (Fig l) , suggesting that ELAM-1 and ICAM-1 mediate distinct adhesion mechanisms. These results are consistent with observations that neutrophil CD18 and endothelial ICAM-1 constitute one adhesion pathway.'^^' Anti-ELAM-1, in combination with anti-CD18 MoAb, also resulted in an additive inhibitory effect, again consistent with the finding that ELAM-1 mediates CD18-independent adhesion of n e~t r o p h i l s .~~,~~ Anti-ELAM-1 and anti-LECM-1 MoAbs show nonadditive inhibition of neutrophil binding to stimulated HLII/EC. We next examined whether neutrophil LECAM-1 could operate in the same adhesion pathway as ELAM-1 (Fig 2) . To exclude a CD18-dependent component, we used CD18-deficient neutrophils isolated from LAD patients. These neutrophils bound stimulated HUVEC with similar efficiency as anti-CD18-treated control neutrophils3' (Figs 1  and 2 ) and, as expected, anti-ICAM-1 MoAb had no effect on this adhesion" (Fig 2) . In contrast, anti-LECAM-1 MoAb and anti-ELAM-1 MoAb both reduced CD18-deficient neutrophil adhesion to stimulated HUVEC to the same extent (Fig 2) , and the combination of both MoAbs did not further reduce adhesion. The results suggested that neutrophil LECAM-1 and endothelial ELAM-1 may participate in the same adhesion pathway.
The DREG-56 and CL2 and CL3 MoAbs were further tested for inappropriate cross-reaction with the wrong Selectin/LECCAM molecule. DREG-56 showed no crossreaction with IL-1-stimulated HUVEC or ELAM-1-transfected L cells, as judged by enzyme-linked immunosorbent assay (ELISA) analysis of monolayers or fluorescence- activated cell sorter (FACS) analysis of harvested cells (data not shown). Similarly, at the concentration of MoAbs used in our functional assays, CL2 and CL3 showed no cross-reaction with peripheral blood neutrophils, as judged by FACS analysis. However, at high concentrations of MoAb (50 pg/mL or fivefold higher than used in functional assays), a small but significant amount of staining above background was seen with CL2, but not with CL3 MoAb. Because CL2 and CL3 showed similar inhibitory effects, we do not believe this cross-reaction is functionally significant. However, to formally exclude the possibility that the CL2 inhibits adhesion by crossreaction with LECAM-1, we pretreated either neutrophils or IL-1-stimulated HUVEC with CL2 F(ab'), MoAb, and then washed out unbound MoAb before the adhesion assays. In summary, pretreatment of neutrophils with CL2 had no inhibitory effect on adhesion to stimulated HUVEC (79% adhesion v 76% for control), while pretreatment of the HUVEC inhibited adhesion significantly (32% adhesion v 76% for control). Furthermore, pretreatment of both populations together had no additional effect over pretreatment of HUVEC alone (32% adhesion for both, n = 2).
Neutrophil adhesion to H U E C stimulated for 8 hours is inhibited by anti-CD18 but not anti-LECAM-1 MoAb.
We next examined neutrophil adhesion to HUVEC that had been stimulated with IL-1 for 8 hours instead of 3 hours. Pober et al" have demonstrated that ELAM-1 expression in vitro peaks at 3 to 4 hours after stimulation and then is rapidly downmodulated by 8 hours. In contrast, ICAM-1 expression remains high over the same time course. Freshly isolated neutrophils, which express LECAM-1 antigen, bind efficiently to both 3-hour and 8-hour stimulated HUVEC (Fig 3) . However, anti-LECAM-1 MoAb reduced neutrophil adhesion only to 3-hour stimulated HUVEC: there was no significant effect on adhesion to 8-hour stimulated HUVEC (Fig 3) . In contrast, anti-ICAM-1 MoAb reduced adhesion to both 3-hour and 8-hour stimulated HUVEC. The combination of anti-LECAM-1 and anti-ICAM-1 MoAbs had an additive inhibitory effect on neutrophil adhesion to 3-hour but not 8-hour stimulated HUVEC (Fig 3) . These results suggested that LECAM-1-mediated adhesion correlates with E L M -1 expression on HUVEC in vitro.
Transendothelial migration involves ICAM-I but not ELAM-I. Transendothelial migration of neutrophils is an adhesion-dependent event that involves both CD18 and ICAM-1." Anti-LECAM-1 MoAbZ5 and anti-ELAM-1 MoAb (Fig 4) have no effect on transendothelial migration. Furthermore, anti-ICAM-1 or antLCD18 MoAb used in combination with anti-ELAM-1 MoAb had no additional effect (Fig 4) . Consistent with these results, CD18-deficient neutrophils that express LECAM-1 are defective in their ability to transmigrate across ICAM-l+, ELAM-1+ HU-VEC." These results, taken together, suggest that neutrophil LECAM-1 and endothelial ELAM-1 are not required for transendothelial migration.
Adhesion of activated neutrophils to stimulated H W E C has both ICAM-I-and ELAM-I-dependent components.
We have reported that activation of neutrophils results in rapid downregulation of LECAM-1.15rz3 These data are consistent with the observation that stimulation of neutrophils reduces the CD184ndependent component of neutrophil adhesion to endothelium5r3* (Fig 5) . Stimulation of CD18-deficient neutrophils with fMLP reduced the percentage of adherent cells from 74% to 29% and, as expected, anti-ICAM-1 had no additional effect on this adhesion. Interestingly, anti-ELAM-1 MoAb had a reduced but reproducibly significant effect on activated CD18-deficient neutrophil adhesion to 3-hour IL-1-stimulated HUVEC (Fig 5) . Adhesion of activated neutrophils from healthy adults was partially inhibited by MoAb against ICAM-1 and ELAM-1. Moreover, these MoAbs used in combination had an additive inhibitory effect (Fig 5) . Taken together, these results are consistent with a neutrophil ligand for ELAM-1 being rapidly downregulated upon activation, resulting in reduced adhesion of activated CD18-deficient neutrophils. However, some component of neutrophil binding to ELAM-1 also appears to involve receptors that are not entirely downregulated, perhaps even upregulated, upon activation.
Neutrophil adhesion to ELAM-ldransfected L cells is inhibited by anti-LECAM-I MoAb.
Neutrophil interaction with ELAM-1 was addressed using mouse L cells transfected with the human ELAM-1 cDNA. Neutrophils bound poorly to mock-or LFA-3-transfected cells, but bound avidly to ELAM-1-transfected cells. Binding was significantly reduced, but not completely eliminated, by treatment of the transfected cells with anti-ELAM-1 MoAb (Fig  6) . Anti-LECAM-1 MoAb reduced adhesion to the same extent, and the combination of both antibodies together 
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had little additional effect (Fig 6) . Antibodies against T200 (CD45), HCAM (CD44), HLA class I, and LFA-3 had no significant effect on binding. CSa-induced activation also significantly reduced adhesion to ELAM-1 transfectants.
DISCUSSION
Neutrophil Mac-l/LFA-1 (CDlla,b/CD18) and endothelial ICAM-1 constitute one well documented adhesion pathway, which appears to be most important in secondary interactions of neutrophils with endothelium (ie, adhesion strengthening and
In contrast, ELAM-1 mediates an adhesion event that is independent of neutrophil CD18.35336 More recently, we have shown that activation of neutrophils results in rapid downregulation of LECAM-1 while Mac-1 is rapidly upregulated, suggesting that LECAM-1 and Mac-1 mediate distinct but complementary adhesion events."z39 The downregulation of LECAM-1 can be induced in vitro by the addition of a variety of chemoattractantS22.23.".39. 40 or by neutrophil exposure to IL-1-stimulated HUVEC." Here, we have tried to dissect the pathways mediated by LECAM-1 and ELAM-1. We have used a strategy similar to that of Shaw et aI4' in their study of lymphocyte-endothelial cell interaction. Shaw et a14' demonstrated that MoAbs against CD2 and LFA-3 have nonadditive inhibitory effects, while both MoAbs have additive inhibitory effects in combination with MoAb against either LFA-1 or ICAM-1. The lack of an additive inhibitory effect found in using combinations of MoAbs is certainly not proof of a receptor-ligand interaction. However, this approach has proved useful in successfully predicting LFA-1-ICAM-1 i n t e r a~t i o n :~~~~ CD2-LFA-3 interaction:' Mac-1-ICAM-1 interaction: and the existence of an alternate ligand for LFA-1,42 termed ICAM-2.
In this report we show that MoAbs against LECAM-1 and ELAM-1 block binding of CDWdeficient neutrophils to stimulated HUVEC to the same extent, and the addition of both MoAbs together does not have an additive effect. Furthermore, the binding of activated LAD neutrophils, which have shed LECAM-1, is reduced.=*" These results are consistent with the observation that activation of neutrophils reduces the CD18-independent component of adhesion to end0thelium.5.~~ Furthermore, these results may also explain in part the observation that IL-8 treatment of neutrophils results in reduced ELAM-l-dependent adhesion to e n d~t h e l i u m ,~~ because IL-8 is known to activate neutrophils and cause downregulation of LECAM-1." Similarly, adhesion of neutrophils to 8-hour stimulated HUVEC, which have downregulated ELAM-1 expression, no longer involves LECAM-1. The transendothelial migration of neutrophils involves CD18 and ICAM-13' but is not affected by MoAbs against LECAM-1" or ELAM-1 (this report). The simplest interpretation of our data is that neutrophil LECAM-1 and endothelial ELAM-1 operate in the same adhesion pathway, possibly as receptor counterstructures.
However, it remains possible that the common element in LECAM-1-and ELAM-1-dependent adhesion is independent of the receptors themselves; LECAM-1 and ELAM-1 could have distinct counterreceptors but still share a requirement for a common, limiting cell surface or intracellular factor for adhesion to occur. Our results must also be reconciled with previously published reports that HL-60, a LECAM-1-negative promyelomonocytic cell line," binds to HUVEC in an ELAM-1-inhibitable manner and binds to ELAM-1-transfected cells.7x8 We have confirmed these observations, although in our assay, neutrophils bind to ELAM transfectants more avidly than HL-60 cells. Furthermore, we have found that the adhesion of activated neutrophils, which have shed LECAM-1, is still partially inhibited by anti-ELAM-1 MoAb. Thus, if LECAM-1 and ELAM-1 are a receptor-ligand pair, then other ligands must also exist for ELAM-1 on neutrophils and possibly for LECAM-1 on HUVEC. LECAM-1 certainly has additional ligands in other settings, because it is involved in lymphocyte binding to high endothelial venules in peripheral lymph nodes," vessels that lack ELAM-1 expression. Multiple ligands for adhesion molecules are common in other systems, notably the integrin family.
The strongest evidence that LECAM-1 may interact with ELAM-1 is that neutrophil binding to ELAM-1 L cell transfectants is inhibited by not only anti-ELAM-1 but also anti-LECAM-1 MoAbs. Although both the anti-LECAM-1 and anti-ELAM-1 MoAbs used in this study inhibited neutrophil binding to ELAM-1 transfectants to the same extent, neither antibody inhibited completely. Furthermore, neutrophil binding to ELAM-1-transfected COS cells was inhibited less efficiently by MoAbs used in this study, perhaps due to the abnormally high levels of ELAM-1 expression in COS cells. In contrast, Bevilacqua et a1 report near complete blocking of HL-60 binding to ELAM-1 COS cell transfectants8v'0 with the H18/7 anti-ELAM-1 MoAb.' However, the H18/7 MoAb (generously provided by Dr F. Luscinskas, Harvard University) in our hands is only slightly better than the CL2 MoAb in inhibiting neutrophil adhesion to stimulated HUVEC. Moreover, in preliminary studies, the H18/7 MoAb is not significantly more effective than CL2 MoAb in inhibiting neutrophil adhesion to ELAM-1-transfected COS cells, even though both MoAbs effectively block HL-60 cell adhesion. It is notable that only HL-60 cells, not neutrophils, are used in other studies on MoAb inhibition of adhesion to ELAM-1-transfected COS cells,8.'o," even though it is a major thesis that ELAM-1 is a neutrophil-specific adhesion molecule. Although HL-60 cells provide a useful model, they differ significantly from normal neutrophils. Undifferentiated HL-60 cells are LECAM-1-negative, VLA+positive, have little or no Mac-1, lack intracellular pools of Mac-1, are difficult to activate, and are unable to transmigrate through endothelial monolayers. The reason for the difference in neutrophil and HL-60 adhesion to ELAM-1 transfectants is unclear, but it is possible that crosslinking of the ELAM-1 ligand on neutrophils, but not on HL-60 cells, induces additional adhesion mechanisms. Under conditions of flow, with shear forces of 1.85 dynes/cm2, we observe essentially complete inhibition of neutrophil adhesion to ELAM-1-transfected L cells with the CL2 MoAb (0. Abbassi, T.K. Kishimoto, C. Lane, L.V. McIntire, C.W. Smith: submitted for publication). Further studies will be required to characterize the unexpectedly complex interaction of neutrophils with ELAM-1 transfectants.
Both LECAM-1 and ELAM-1 are members of the LECCAM/selectin family of adhesion proteins, which are characterized by a unique protein motif containing a lectin domain.6 The lectin domain has been shown to be critical for LECAM-1 function in its role as a homing receptor for peripheral lymph node HEV.45 The DREG MoAbs appear to map to the lectin d~m a i n '~.~ (B. Bowen, unpublished observations); however, preliminary experiments suggest that CD18-deficient neutrophil adhesion to stimulated HUVEC is not affected by carbohydrates that inhibit binding of lymphocytes to peripheral lymph node HEV. Direct interaction of two adhesion molecules within the same family would not be surprising because a number of adhesion molecules are thought to be derived from an ancestoral molecule that participates in homophilic interactions. As tissue-and cell-specialization has increased, these ancestoral adhesion molecules may have diverged to form more specialized, but related molecules that are still capable of interaction. It is significant that all three selectins/ LECCAMs are involved in leukocyte interaction with vascular endothelium or platelets. Similarly, lectin receptors may have diverged to allow recognition of carbohydrates that modify multiple glycoproteins and, hence, may have multiple ligands.
While this manuscript was under review, four groups have elegantly shown, by a variety of strategies, that the carbohydrate epitope sialyl Lewis X (SW) is a ligand for ELAM-l.649 Thus, it is significant that LECAM-1 is one of the neutrophil proteins that bears the S W epitope (L. Picker, University of Texas Southwestern Medical Center, personal communication, February 1991). This finding is consistent with our results that suggest that ELAM-1 may interact with LECAM-1. These results also offer a possible explanation of why LECAM-1 on lymphocytes do not mediate binding to ELAM-1, because lymphocytes, in general, do not express the S W epitope. Walz et a149 have further shown that activated neutrophils release SLe"-bearing proteins into the supernatant, which can inhibit ELAM-1-dependent adhesion. These results are consistent with our observation that LECAM-1 is rapidly shed following activati0n.3~ Further studies will be needed to address whether all SW-bearing glycoproteins and glycolipids are equally capable of supporting ELAh4-l-dependent adhesion, or whether the presentation of the S W epitope is more accessible on some proteins, such as LECAM-1, than on others.
